REScUE
Loss of RESponse to Ustekinumab treated by dose Escalation
EudraCT number: 2018-004269-14
En cours d’inclusion
Investigateur: Dr. Peter Bossuyt
REScUE-OLE
An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn’s disease previously included in the loss of RESponse to Ustekinumab treated by dose Escalation study (REScUE-OLE).
EudraCT Number: 2021-000345-41
En cours d’inclusion
Investigateur: Dr. Lieven Pouillon
I-CARE
Ibd CAncer and seRious infections in Europe
EudraCT NUMBER: 2014-004728-23
En cours
Investigateur: Prof. Dr. Laurent Peyrin-Biroulet,
Investigateurs pour la Belgique: Prof. Dr. Jean-François Rahier - Dr. Filip Baert
PACIFIC
Study of the inter-individual variation of PhArmaCo-kinetics of Infliximab during treatment Induction in patients with Crohn’s disease and ulcerative Colitis (PACIFIC)- EudraCT Number: 2015-004618-10.
Terminées/en cours d’analyse
Investigateur: Prof. Dr. Denis Franchimont
SPARE
A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy.
EudraCT- Number: 2014-002311-41
Terminées/en cours d’analyse
Investigateur: Prof. Dr. Edouard Louis